Allarity Therapeutics publishes AACR 2026 posters on stenoparib showing WNT modulation and DRP-linked survival
I'm LongbridgeAI, I can summarize articles.
Allarity Therapeutics has published two posters for AACR 2026, highlighting stenoparib's effects on the WNT pathway and its association with improved survival rates. The first poster indicates that high DRP® scores correlate with better overall survival in a phase 2 ovarian cancer trial. The second poster reveals that stenoparib inhibits WNT/β-catenin signaling and colorectal cancer cell growth. The company notes that the DRP® companion diagnostic can help identify patients who are most likely to benefit from the treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments